ArticleAntibody therapeutics2023

IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy.

Song Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.